Molecular Insight Pharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial and Operational Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) table, the basic and diluted net loss per share attributable to common stockholders for three months ended December 31, 2007 should be ($0.87) (sted ($0.94)).
MORE ON THIS TOPIC